Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort ascending | Description |
---|---|---|---|---|---|---|---|---|
PHENYTOIN SODIUM INJECTION | OTHER COMPONENTS/Alcohol and Propylene Glycol Content | First Supplement to USP37–NF32 | 6684 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Standard solution: Change Internal standard stock solution to: Internal standard solution |
Sodium Sulfite, Anhydrous | REAGENTS/Reagent Specifications | USP36–NF31 | 1196 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 2: Change [7753-83-7] to: [7757-83-7] |
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION | ASSAY/Procedure | USP37–NF32 | 4766 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Sample stock solution: Change sulfacetamide to: sulfacetamide sodium AND Line 1 of Sample solution: Change sulfacetamide to: sulfacetamide sodium |
DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS | IMPURITIES/Limit of Ibuprofen Related Compound C | USP37–NF32 | 2651 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Analysis: Change RU = peak area ratio of ibuprofen to valerophenone from the Sample solution RS = peak area ratio of ibuprofen to valerophenone from the Standard solution to: RU = peak area ratio of… Read More |
LINDANE CREAM | ASSAY/Procedure/Chromatographic system/Temperatures | USP37–NF32 | 3561 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | After the Injection port subsection: Add a new subsection Detector: 250° |
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS | ASSAY | Second Supplement to USP36–NF31 | 6580 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Procedure: Change Inject the Sample solution within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light. |
POWDERED ECHINACEA PALLIDA EXTRACT | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5359 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea pallida Extract RS |
PYRANTEL PAMOATE | ASSAY/Procedure | USP37–NF32 | 4491 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Mobile phase: Change acetic acid to: glacial acetic acid AND Line 1 of Column efficiency: Change NLT 8000 theoretical plates to: NLT 8000 theoretical plates for the pyrantel peak |
ALCOHOL IN DEXTROSE INJECTION | ASSAY/Dextrose | USP37–NF32 | 1637 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 15 of Analysis: Change A = length of the polarimeter tube (mm) to: A = 100 mm divided by the length of the polarimeter tube (mm) |
GENERAL NOTICES TO USP-NF | 6. TESTING PRACTICES AND PROCEDURES/6.50. Preparation of Solutions | First Supplement to USP37–NF32 | 6291 | 25-Jul-2014 | 1-Aug-2014 | USP38–NF33 | USP38–NF33 | Line 6 of 6.50.20. Solutions: Change An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume. An expression such as “(20:5:2… Read More |
MAGNESIUM ALUMINUM SILICATE | IMPURITIES/Arsenic, Method I <211> | USP36–NF31 | 2073 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Standard preparation: Change Prepare as directed in the chapter. to: Transfer 5.0 mL (5 μg of arsenic) of the Standard Arsenic Solution to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Delete: Control preparation… Read More |
TAMSULOSIN HYDROCHLORIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 4 | USP37–NF32 | 4830 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 9 of the second calculation: Change V = volume of Buffer stage medium, 1000 mL to: V = volume of Buffer stage medium, 500 mL |
DOXEPIN HYDROCHLORIDE ORAL SOLUTION | ASSAY/Procedure | USP37–NF32 | 2713 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Standard solution: Change Dilute 4.0 of Standard stock solution to: Dilute 4.0 mL of Standard stock solution |
MAPROTILINE HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP37–NF32 | 3655 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Analysis: Change Determine the labeled amount of maprotiline hydrochloride to: Determine the percentage of the labeled amount of maprotiline hydrochloride |
CALCIUM SULFATE | ASSAY/Procedure | First Supplement to USP36–NF31 | Online | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 14 of Analysis: Change Result = [(V × N × F)/W] × 100 to: Result = [(V × M × F)/W] × 100 AND Line 15 of Analysis: Change V = volume of titrant consumed by the Sample (mL) N = actual… Read More |
POWDERED ECHINACEA PURPUREA EXTRACT | COMPOSITION | USP37–NF32 | 5371 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 14 of Analysis in Content of Total Phenols: Change CS = concentration of the relevant analyte in the corresponding Standard solution CU = concentration of Echinacea purpurea in the Sample solution (mg/mL) to:… Read More |
PYRANTEL PAMOATE | OTHER COMPONENTS/Content of Pamoic Acid | USP37–NF32 | 4491 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Mobile phase: Change acetic acid to: glacial acetic acid |
ALUMINA, MAGNESIA, CALCIUM CARBONATE, AND SIMETHICONE CHEWABLE TABLETS | ASSAY/Magnesium Hydroxide | USP37–NF32 | 1674 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5 of Magnesium stock solution: Change Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg) to: Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of… Read More |
CLINDAMYCIN PALMITATE HYDROCHLORIDE | ASSAY/Procedure | USP36–NF31 | 3031 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Acceptance criteria: Change NLT 540 μg to: NLT 540 μg/mg |
THIOTHIXENE | Limit of (E)-thiothixene/Standard preparations | USP37–NF32 | 4942 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of C: Change Transfer about 200 mg of thiothixene to: Transfer about 200 mg of Thiothixene |
ESCITALOPRAM TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP37–NF32 | 2852 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Buffer: Change phosphoric to: phosphoric acid |
METHADONE HYDROCHLORIDE ORAL SOLUTION | OTHER COMPONENTS | USP37–NF32 | 3744 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Alcohol Determination: Change gas–liquid chromatographic procedure to: gas chromatographic procedure |
ONDANSETRON INJECTION | Assay | Second Supplement to USP36–NF31 | Online | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36 / 329.82)(25C / V)(rU / rS) to: (293.36 / 329.83)(25C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |
POWDERED DECAFFEINATED GREEN TEA EXTRACT | COMPOSITION/Content of Polyphenols/Chromatographic system | USP37–NF32 | 5438 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Column: Change 4.6-mm 6 25-cm; to: 4.6-mm × 25-cm; |
PYRAZINAMIDE | Identification/B: Ultraviolet Absorption <197U> | USP37–NF32 | 4493 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4: Change on the dried basis to: on the anhydrous basis |
ALUMINUM CHLOROHYDRATE SOLUTION | ASSAY/Procedure 4 | USP37–NF32 | 1686 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Analysis: Change anhydrous aluminum dichlorohydrate to: anhydrous aluminum chlorohydrate |
MELPHALAN TABLETS | Dissolution <711> | USP36–NF31 | 4232 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Mobile phase: Change Prepare a filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1500:500:2:2:0.4). Make adjustments if necessary (see System Suitability under Chromatography <621>). to: … Read More |
TRIACETIN | ASSAY/Procedure/Titrimetric system | USP37–NF32 | 5031 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2: Change (See Titrimetry <541>, Residual Titrations.) to: (See Titrimetry <541>.) AND Line 1 of Mode: Change Direct titration to: Residual titration |
FOSPHENYTOIN SODIUM INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 3096 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Before USP Fosphenytoin Sodium RS: Add USP Endotoxin RS |
MICONAZOLE INJECTION | IDENTIFICATION/A./Chromatographic system | USP37–NF32 | 3831 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Spray reagent: Change (Dragendorff’s reagent) to: (Dragendorff’s TS) |
POWDERED DECAFFEINATED GREEN TEA EXTRACT | SPECIFIC TESTS | USP37–NF32 | 5438 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5 of Analysis in Limit of Gallic Acid: Change Separately calculate the percentages of gallic acid to: Calculate the percentage of gallic acid AND Line 5 of Analysis in Limit of Caffeine: Change Separately calculate the percentages of caffeine … Read More |
QUINIDINE GLUCONATE | DEFINITION | USP37–NF32 | 4512 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6: Change quinidine sulfate to: quinidine gluconate |
AMINOSALICYLATE SODIUM | ASSAY/Procedure | USP37–NF32 | 1745 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 15 of Analysis: Change CU = concentration of aminosalicylate in the Sample solution (mg/mL) to: CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL) |
ONDANSETRON ORAL SOLUTION | Related compounds | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)10,000(1 / F)(1 / V)(CS / CA)(ri / rS) to: (293.36 / 329.83)10,000(1 / F)(1 / V)(CS / CA)(ri… Read More |
VALSARTAN | IMPURITIES | USP37–NF32 | 5115 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Footnote a of Table 1: Change (S)-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine. AND Footnote b of Table 1: Change (S)-… Read More |
GADOPENTETATE DIMEGLUMINE INJECTION | IDENTIFICATION/B. | USP37–NF32 | 3113 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2: Change 364.8 nm to: 368.4 nm |
NYSTATIN | DEFINITION | USP37–NF32 | 4035 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6: Change extemporaneous solution to: extemporaneous preparation |
HOLY BASIL LEAF | COMPOSITION/Content of Triterpenes | USP37–NF32 | 5454 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4 of Standard solution B: Change 0.45-μL to: 0.45-μm |
QUINIDINE GLUCONATE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | USP37–NF32 | 4515 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of System suitability solution: Change dihydroquinidine chloride to: dihydroquinidine hydrochloride |
AMIODARONE HYDROCHLORIDE | IMPURITIES/Organic Impurities/Procedure 1 | USP37–NF32 | 1750 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Acceptance criteria: Change Standard solution B is not more intense to: the Sample solution is not more intense |
ONDANSETRON ORAL SOLUTION | Assay | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)100(C/V)(rU / rS) to: (293.36 / 329.83)100(C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |
VALSARTAN | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5115 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of USP Valsartan Related Compound A RS: Change (R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine. to: N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine. AND Line 2 of USP Valsartan Related… Read More |
GRISEOFULVIN CAPSULES | PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity | USP37–NF32 | 3196 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6 of Analysis: Change Result = (AU/AS) × (CS/CU) × P × 100 to: Result = (AU/AS) × (CS/CU) × P × F × 100 AND… Read More |
OLMESARTAN MEDOXOMIL | CHEMICAL INFORMATION | USP37–NF32 | 4057 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of the chemical name: Change methyl ester to: methyl ester; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
DESCRIPTION AND SOLUBILITY | Carmellose | USP37–NF32 | 1486 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4: Change Suspending and/or viscosity increasing agent; to: Suspending and/or viscosity-increasing agent; |
POWDERED HOLY BASIL LEAF | COMPOSITION/Content of Triterpenes | USP37–NF32 | 5456 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4 of Standard solution B: Change 0.45-μL to: 0.45-μm |
RIBAVIRIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Procedure 1/Chromatographic system | USP37–NF32 | 4562 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Column: Change 7-µm packing L17 to: 9-µm packing L17 |
CARBAMAZEPINE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | USP37–NF32 | 2123 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Sample stock solution B: Change Standard stock solution to: Sample stock solution A |
SODIUM ACETATE | IMPURITIES/Inorganic Impurities/Potassium | USP36–NF31 | 5147 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Sample solution: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of Analysis: Change To 5 mL of Sample solution add to: To the Sample… Read More |
ECHINACEA ANGUSTIFOLIA | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5343 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea angustifolia Extract RS |